1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>Canada

Contentious Pricing Mechanism Adopted In Canada But Only For ‘A Brief Period’

 
• By Neena Brizmohun

Drug companies are unhappy about a new median price test and the exclusion of the Consumer Price Index in the amended interim guidance from the Patented Medicine Prices Review Board

The PMPRB's mandate is to ensure that medicine prices are not excessive in Canada • Source: Shutterstock

Canada’s Patented Medicine Prices Review Board (PMPRB) has adopted an amended interim guidance that includes a controversial pricing mechanism, but has said the guidance would only apply for “a brief period.” The PMPRB is planning to launch a consultation soon about new guidelines, which it said it would approach “with a fresh and open mind.”

The PMPRB, whose mandate is to ensure that medicine prices are not excessive, announced the move on 27 September, after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

Faster HTA Reviews & Pricing Reform Could Help Fix Canada’s Drug Access Woes

 
• By Eliza Slawther

Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

More from North America